We are live on ! Find out more
Birchview Capital

Birchview Capital Portfolio holdings

AUM $173M Turnover 41.05%
1-Year Est. Return 89.27%
This Fund
S&P 500
This Quarter Est. Return
-1.87%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$163M
AUM Growth
-$8.83M
Cap. Flow
+$356K
Cap. Flow %
0.22%
Top 10 Hldgs %
92.23%
Holding
44
New
1
Increased
5
Reduced
–
Closed
3
Avg Time Held
1.4 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.2 years

Sector Composition

Rank Sector Weight
1 Healthcare 95.77%
2 Energy 3.29%
3 Industrials 0.32%
4 Consumer Staples 0.19%
5 Miscellaneous 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$89.9M 55.35%
777,051
– –
2014 Q4
8 quarters
AXDX icon
2
DELISTED
Accelerate Diagnostics
AXDX
$45.1M 27.78%
217,580
– –
2014 Q4
8 quarters
EQT icon
3
EQT
EQT
$31.7B
$2.77M 1.7%
77,705
– –
2014 Q4
8 quarters
VRML
4
DELISTED
Vermillion
VRML
$2.58M 1.59%
2,717,514
– –
2014 Q4
8 quarters
MASI icon
5
DELISTED
Masimo
MASI
$2.47M 1.52%
36,600
– –
2014 Q4
8 quarters
BIOL icon
6
DELISTED
Biolase
BIOL
$1.8M 1.11%
103
– –
2014 Q4
8 quarters
OVV icon
7
Ovintiv
OVV
$17.2B
$1.55M 0.96%
26,460
– –
2014 Q4
8 quarters
TSRO
8
DELISTED
Tesaro
TSRO
$1.34M 0.82%
9,950
– –
2015 Q4
4 quarters
CFRX
9
DELISTED
ContraFect
CFRX
$1.27M 0.78%
906
– –
2015 Q2
6 quarters
OXFD
10
DELISTED
Oxford Immunotec Global
OXFD
$1.01M 0.62%
67,303
– –
2015 Q3
5 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$16.5B
$975K 0.6%
25,200
– –
2015 Q3
5 quarters
MRK icon
12
Merck
MRK
$340B
$883K 0.54%
15,720
– –
2014 Q4
8 quarters
QDEL icon
13
QuidelOrtho
QDEL
$657M
$835K 0.51%
38,975
– –
2014 Q4
8 quarters
NXTM
14
DELISTED
NxStage Medical
NXTM
$739K 0.45%
28,200
– –
2014 Q4
8 quarters
WMGI
15
DELISTED
Wright Medical Group
WMGI
$689K 0.42%
30,000
– –
2015 Q4
4 quarters
VCYT icon
16
Veracyte
VCYT
$2.06B
$617K 0.38%
79,767
+45,200
+131% +$338K
2016 Q3
1 quarter
CORT icon
17
Corcept Therapeutics
CORT
$7.33B
$581K 0.36%
80,000
– –
2015 Q4
4 quarters
OMED
18
DELISTED
OncoMed Pharmaceuticals
OMED
$545K 0.34%
70,689
– –
2014 Q4
8 quarters
PXD icon
19
DELISTED
Pioneer Natural Resources
PXD
$541K 0.33%
3,000
– –
2014 Q4
8 quarters
SIEN
20
DELISTED
Sientra
SIEN
$539K 0.33%
6,330
– –
2015 Q3
5 quarters
SITO
21
DELISTED
Sito Mobile
SITO
$517K 0.32%
140,000
– –
2016 Q2
2 quarters
CTRA icon
22
DELISTED
Coterra Energy
CTRA
$491K 0.3%
21,000
– –
2014 Q4
8 quarters
ARAY icon
23
Accuray
ARAY
$7.32M
$438K 0.27%
2,383
– –
2014 Q4
8 quarters
VNDA icon
24
Vanda Pharmaceuticals
VNDA
$230M
$351K 0.22%
+22,000
New +$354K
2016 Q4
0 quarters
XNCR icon
25
Xencor
XNCR
$2.58B
$324K 0.2%
12,300
– –
2015 Q1
7 quarters

Similar funds

Birchview Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Birchview Capital held 44 positions worth $163M, down 5.2% from $171M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q4 2016 filing shows 1 new, 5 increased and 3 closed positions. Its largest new stake was Vanda Pharmaceuticals: 22,000 shares worth $351K. The largest sale was Kura Oncology, an estimated $369K.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q4 2016 buy was Vanda Pharmaceuticals: 22,000 shares worth $351K.
  • Birchview Capital added most to Veracyte in Q4 2016, an estimated $338K increase.
  • Birchview Capital fully exited Kura Oncology in Q4 2016, selling an estimated $369K.
  • Birchview Capital's ten largest holdings make up 92% of its $163M portfolio in Q4 2016.
  • Birchview Capital opened 1 new position and closed 3 in Q4 2016.
  • Birchview Capital's portfolio value fell 5.2% quarter-over-quarter to $163M.

Based on Birchview Capital's 13F filing for Q4 2016, filed 9 Feb 2017.